Oncogene-induced senescence in pituitary adenomas and carcinomas

Hormones

Volumn 11, Issue 3, 2012, Pages 297-307

  Alexandraki, Krystallenia I ^a   Khan, Mohammed Munayem ^a   Chahal, Harvinder S ^a   Dalantaeva, Nadezhda S ^a   Trivellin, Giampaolo ^a   Berney, Dan M ^a   Caron, Philippe ^b   Popovic, Vera ^c   Pfeifer, Marija ^d   Jordan, Suzanne ^a   Korbonits, Márta ^a   Grossman, Ashley B ^a  

^a QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^b TOULOUSE UNIVERSITY HOSPITAL   (France)

^c CLINICAL CENTER OF SERBIA   (Serbia)

^d UNIVERSITY MEDICAL CENTRE LJUBLJANA   (Slovenia)

Author keywords

p16; p21; Pituitary adenoma; Pituitary carcinoma; Senescence; galactosidase

Indexed keywords

BETA GALACTOSIDASE; CORTICOTROPIN; FOLLITROPIN; GROWTH HORMONE; MESSENGER RNA; PROLACTIN; PROTEIN P16; PROTEIN P21;

ARTICLE; CANCER GROWTH; CANCER INHIBITION; CELL SPECIFICITY; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; CORTICOTROPIN RELEASE; FOLLITROPIN RELEASE; GROWTH HORMONE RELEASE; HUMAN; HUMAN TISSUE; HYPOPHYSIS; HYPOPHYSIS ADENOMA; HYPOPHYSIS CARCINOMA; HYPOPHYSIS DISEASE; HYPOPHYSIS FUNCTION; IMMUNOCHEMISTRY; ONCOGENE; ONCOGENE INDUCED SENESCENCE; POLYMERASE CHAIN REACTION; PROLACTIN RELEASE; PROTEIN EXPRESSION; PROTEIN FUNCTION;

EID: 84864864628     PISSN: 11093099     EISSN: None     Source Type: Journal    
DOI: 10.14310/horm.2002.1358     Document Type: Article

References (29)

1. Fernandez A, Karavitaki N, Wass JA, 2010 Prevalence of pituitary adenomas: a community-based, cross-sectional study in Banbury (Oxfordshire, UK). Clin Endocrinol (Oxf) 72: 377-382.
2. Scheithauer BW, Gaffey TA, Lloyd, et al, 2006 Pathobiology of pituitary adenomas and carcinomas. Neurosurgery 59: 341-353.
3. Donangelo I, Melmed S, 2005 Pathophysiology of pituitary adenomas. J Endocrinol Invest 28(11 Suppl International): 100-105.
4. Dworakowska D, Wlodek E, Leontiou CA, et al, 2009 Activation of RAF/MEK/ERK and PI3K/AKT/mTOR pathways in pituitary adenomas and their effects on downstream effectors. Endocr Relat Cancer 16: 1329-1338.
5. Lowe SW, Cepero E, Evan G, 2004 Intrinsic tumour suppression. Nature 432: 307-315.
6. Sherr CJ, 2004 Principles of tumour suppression. Cell 116: 235-246.
7. Kuilman T, Michaloglou C, Vredeveld LC, et al, 2008 Oncogene-induced senescence relayed by an interleukindependent inflammatory network. Cell 133: 1019-1031.
8. Mooi WJ, Peeper DS, 2006 Oncogene-induced cell senescence-halting on the road to cancer. N Engl J Med 355: 1037-1046.
9. Quereda V, Malumbres M, 2009 Cell cycle control of pituitary development and disease. J Mol Endocrinol 42: 75-86.
10. Collado M, Serrano M, 2006 The power and the promise of oncogene-induced senescence markers. Nat Rev Cancer 6: 472-476.
11. Arzt E, Chesnokova V, Stalla GK, Melmed S, 2009 Pituitary adenoma growth: a model for cellular senescence and cytokine action. Cell Cycle 8: 677-678.
12. Going JJ, Stuart RC, Downie M, Fletcher-Monaghan AJ, Keith WN, 2002 'Senescence-associated' betagalactosidase activity in the upper gastrointestinal tract J Pathol 196: 394-400.
13. Itahana K, Campisi J, Dimri GP, 2007 Methods to detect biomarkers of cellular senescence: the senescenceassociated beta-galactosidase assay. Methods Mol Biol 371: 21-31.
14. Chesnokova V, Zonis S, Kovacs K, et al, 2008 p21(Cip1) restrains pituitary tumour growth. Proc Natl Acad Sci U S A. 105: 17498-17503.
15. Chesnokova V, Zonis S, Zhou C, et al, 2011 Lineage-Specific Restraint of Pituitary Gonadotroph Cell Adenoma Growth. PLoS ONE 6: e17924.
16. Melmed S, 2011 Pathogenesis of pituitary tumours. Nat Rev Endocrinol 7: 257-266.
17. Chesnokova V, Zonis S, Rubinek T, et al, 2007 Senescence Mediates Pituitary Hypoplasia and Restrains Pituitary Tumour Growth. Cancer Res 67: 10564-10572.
18. Machiavelli G, Cotignola J, Danilowicz K, et al, 2008 Expression of p16(INK4A) gene in human pituitary tumours. Pituitary 11: 71-75.
19. Quereda V, Martinalbo J, Dubus P, Carnero A, Malumbres M, 2007 Genetic cooperation between p21Cip1 and INK4 inhibitors in cellular senescence and tumour suppression. Oncogene 26: 7665-7674.
20. Korbonits M, Chahal HS, Kaltsas G, et al, 2002 Expression of phosphorylated p27(Kip1) protein and Jun activation domain-binding protein 1 in human pituitary tumours. J Clin Endocrinol Metab 87: 2635-2643.
21. Norton AJ, Jordan S, Yeomans P, 1994 Brief, high-temperature heat denaturation (pressure cooking): a simple and effective method of antigen retrieval for routinely processed tissues. J Pathol 173: 371-379.
22. Sabin RJ, Anderson RM. Cellular Senescence-its role in cancer and the response to ionizing radiation. Genome Integr 2: 7.
23. Mooi WJ, 2009 Oncogene-induced cellular senescence: causal factor in the growth arrest of pituitary microadenomas? Horm Res 71: Suppl 2: 78-81.
24. Zhou BP, Liao Y, Xia W, Spohn B, Lee MH, Hung MC, 2001 Cytoplasmic localization of p21Cip1/WAF1 by Aktinduced phosphorylation in HER-2/neu-overexpressing cells. Nat Cell Biol 3: 245-252.
25. Weinberg WC, Denning MF, 2002 P21Waf1 control of epithelial cell cycle and cell fate. Crit Rev Oral Biol Med 13: 453-464.
26. Neto AG, McCutcheon IE, Vang R, Spencer ML, Zhang W, Fuller GN, 2005 Elevated expression of p21 (WAF1/Cip1) in hormonally active pituitary adenomas. Ann Diagn Pathol 9: 6-10.
27. Farrell WE, Clayton RN, 2003 Epigenetic change in pituitary tumourigenesis. Endocr Relat Cancer 10: 323-330.
28. Evangelou K, Bramis J, Peros I, et al, 2004 Electron microscopy evidence that cytoplasmic localization of the p16(INK4A) "nuclear" cyclin-dependent kinase inhibitor (CKI) in tumor cells is specific and not an artifact. A study in non-small cell lung carcinomas. Biotech Histochem 79: 5-10.
29. Zhao P, Hu YC, Talbot IC, 2003 Expressing patterns of p16 and CDK4 correlated to prognosis in colorectal carcinoma. World J Gastroenterol 9: 2202-2206.